Condition: Diffuse Large B-cell Lymphoma (DLBCL) · Sponsor: Regeneron Pharmaceuticals
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"), can also participate in this study. This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study. The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab (the comparator drug), and chemotherapy, the current standard of care treatment approved for DLBCL. Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug when combined with chemotherapy * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the stud…
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic - Arizona | Scottsdale, Arizona, United States | Recruiting |
| David Geffen School of Medicine at UCLA | Los Angeles, California, United States | Recruiting |
| University of California Irvine Medical Center | Orange, California, United States | Recruiting |
| University of California (UC) Davis | Sacramento, California, United States | Recruiting |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| St Vincent Ascension at Peyton Manning Childrens Hospital | Indianapolis, Indiana, United States | Recruiting |
| Investigative Clinical Research of Indiana | Noblesville, Indiana, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids, Michigan, United States | Recruiting |
+ 156 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06091865